Prelude Therapeutics Incorporated (PRLD) Signs Trial-Supply Deal With Lilly for PRT13722 Combos

Prelude Therapeutics (PRLD) and Lilly agreed to a clinical trial and supply deal to study PRT13722 with abemaciclib and imlunestrant for HR+/HER2- breast cancer. The FDA cleared the IND, and Phase 1 enrollment is expected to start in Q4 2026, according to the companies.

Original reporting
Published Oct 13, 2026, 11:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 11:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Prelude Therapeutics Incorporated (PRLD) Signs Trial-Supply Deal With Lilly for PRT13722 Combos — source image
Decision brief

The 30-second read

$PRLDBullishMed
01

Why it matters

The deal provides Prelude with a validated partner and supply chain, potentially accelerating IND progress and attracting further capital.

02

Market read

First disclosure of a strategic partnership that could materially affect Prelude's valuation and the oncology biotech sector.

03

What to watch

Potential dilution from future financing needs and the timeline to meaningful data could delay any price impact.

Relevance 8/10Novelty 8/10Timing: upon announcement

Background

Prelude Therapeutics is a clinical‑stage biotech focused on oncology; Eli Lilly is a large pharma with established breast‑cancer drugs.

Company-level read

Ticker impact

$PRLDBullishMedium confidence
Context

Prelude Therapeutics announced a supply and trial collaboration with Eli Lilly for PRT13722, marking the first public disclosure of the deal.

Expected impact

likely upward pressure as investors price in the Lilly collaboration

Evidence & confidence

Early‑stage biotech deals with large pharma often boost valuation despite execution risk.

Market effects

May signal increased interest in HR+/HER2‑ breast cancer therapeutics, benefiting peers in oncology biotech.

Limited to US biotech sector; no broader regional effect.

Modest, confined to specialty pharma and biotech investors.

Counterpoint

The collaboration is early‑stage; execution risk and lack of data could keep the stock flat or lead to disappointment.

Key entities

  • Prelude Therapeutics Incorporated

    Clinical‑stage oncology biotech.

  • Eli Lilly and Company

    Large pharmaceutical partner.

Related articles

$PRLDMed

Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Prelude Therapeutics Inc (PRLD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Enrollment of Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer is underway; initial proof of concept data anticipated

$PRLDMed

H.C. Wainwright reiterates Prelude Therapeutics stock rating at buy

H.C. Wainwright reiterated a Buy rating and $8.00 price target for Prelude Therapeutics (PRLD), which trades at $3.56. The company announced a clinical trial collaboration with Eli Lilly. Prelude's stock has gained 174% over the past year, with a strong balance sheet. Analysts highlight the potential of its KAT6A-selective degrader, PRT13722, and other drugs in development.

$PRLDMed

Citizens reiterates Prelude Therapeutics stock rating on Lilly deal

Citizens reiterated a Market Outperform rating and $6.00 price target for Prelude Therapeutics (PRLD) after its collaboration with Eli Lilly. PRLD shares are at $3.56, up 174% in a year. The agreement focuses on evaluating PRT13722 in breast cancer trials. Prelude expects clinical updates in 2027 and has a strong cash position of $155.2 million. Other analysts, including JPMorgan and H.C. Wainwright, have also given positive ratings to PRLD.

$PRLDMedAI 8/10

Prelude Therapeutics, Lilly Partner To Evaluate PRT13722 In Breast Cancer Trial

Prelude Therapeutics (PRLD) and Eli Lilly (LLY) will collaborate to evaluate PRT13722 in a breast cancer trial. The Phase 1 study will test PRT13722 with Lilly's Verzenio and Inluriyo in HR+/HER2- breast cancer patients. Prelude's IND application was cleared by the FDA, with enrollment expected in Q4 2026. Preclinical data showed PRT13722's potential as a monotherapy and in combination therapies. PRLD's stock closed at $3.74 on Monday, up 6.42% in pre-market trading.